News

More patients are surviving long after their cancer diagnoses, putting a new emphasis on survivorship care planning, explained Deborah A. Boyle, MSN, RN, AOCNS, FAAN.

The FDA approved the VENTANA PD-L1 (SP142) Assay as the first companion diagnostic to aid in identifying patients with triple-negative breast cancer who are eligible for treatment with Tecentriq (atezolizumab) plus chemotherapy.

Rivaroxaban (Xarelto) significantly lowered the incidence of venous thromboembolism (VTE) or death due to VTE during the intervention period with the agent in patients with solid tumors or lymphoma, according to results from the CASSINI trial.

The Food and Drug Administration has granted an accelerated approval to the frontline combination of atezolizumab (Tecentriq) plus nab-paclitaxel (Abraxane) for patients with unresectable locally advanced or metastatic PD-L1–positive triple-negative breast cancer (TNBC)

Chemotherapy-induced nausea and vomiting (CINV) is a major issue in patients with blood cancers who are undergoing chemotherapy before receiving hematopoietic stem cell transplantation.

In an interview with Oncology Nursing News, Christopher R. Friese, PhD, RN, AOCN, FAAN, discussed his study, and though the results were not what he expected, Friese still emphasized the need for proper education for oncology nurses.

Alex Trebek, the long-time host of the popular game show Jeopardy!, announced that he was diagnosed with stage 4 pancreatic cancer.

The FDA has granted a priority review designation to a new drug application (NDA) for fedratinib as a treatment for patients with myelofibrosis.

When handling chemotherapy and other potentially dangerous anti-cancer drugs, there are steps that oncology nurses should take to protect themselves and their colleagues, according to a recent presscast from the American Society of Clinical Oncology (ASCO).

The FDA has expanded the approval of aprepitant (Cinvanti) injectable emulsion to include a 2-minute intravenous (IV) use for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV).

Here are the top 5 Oncology Nursing News stories for February 2019.

A liquid biopsy test detected all of the guideline-recommended biomarkers in newly diagnosed patients with metastatic non-small cell lung cancer at a similar rate but faster turnaround time to that of tissue genotyping.

The FDA has approved subcutaneous use of trastuzumab (Herceptin) and hyaluronidase-oysk injection (Herceptin Hylecta) in combination with chemotherapy for the treatment of select patients with HER2-positive early breast cancer, and alone or in combination with paclitaxel in patients with metastatic HER2-positive breast cancer who have received at least 1 prior chemotherapy regimen.

Many younger patients see more than one doctor and face misdiagnoses before being given a diagnosis of colorectal cancer (CRC), according to recent research presented during a webcast ahead of the 2019 AACR Annual Meeting.

The FDA has granted a priority review designation to a supplemental new drug application (sNDA) for the R2 regimen of lenalidomide (Revlimid) plus rituximab (Rituxan) for use in patients with previously treated follicular lymphoma and marginal zone lymphoma (MZL).

The FDA sent out a warning letter about using thermography in place of mammography to diagnose breast cancer. Here’s how oncology nurses can help.

The Food and Drug Administration approved TAS-102 (Lonsurf; trifluridine/tipiracil) for the treatment of patients with pretreated metastatic gastric adenocarcinoma or gastroesophageal junction cancer.

Cervical cancer and precancers have decreased in recent years, thanks to the HPV vaccine.

Palliative care can improve outcomes in patients with cancer but is not used as often as it could be.

The FDA granted a priority review to ivosidenib (Tibsovo) for the treatment of patients with newly diagnosed acute myeloid leukemia (AML) with an IDH1 mutation who are not eligible for standard therapy.

Pembrolizumab was granted a priority review to treat patients with advanced small-cell lung cancer whose disease progressed on 2 or more lines of prior therapy.

The FDA granted a priority review to polatuzumab vedotin in combination with bendamustine plus rituximab (Rituxan) for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

The FDA granted a priority review to entrectinib for the treatment of adult and pediatric patients with NTRK fusion-positive, locally advanced or metastatic solid tumors and for metastatic, ROS1-positive non-small cell lung cancer.

The FDA approved pembrolizumab (Keytruda) for the adjuvant treatment of patients with resected, high-risk stage III melanoma.

Event to Fund Cutting-Edge Pediatric Cancer Research